Deutsche Bank Analysts Give Bayer (BAYN) a €115.00 Price Target

Deutsche Bank set a €115.00 ($133.72) target price on Bayer (FRA:BAYN) in a research note published on Monday. The brokerage currently has a buy rating on the healthcare company’s stock.

Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Bayer in a research report on Thursday, November 29th. Goldman Sachs Group set a €109.00 ($126.74) target price on shares of Bayer and gave the company a buy rating in a research report on Tuesday, November 13th. Jefferies Financial Group set a €77.00 ($89.53) target price on shares of Bayer and gave the company a neutral rating in a research report on Tuesday, October 23rd. Sanford C. Bernstein set a €89.00 ($103.49) target price on shares of Bayer and gave the company a buy rating in a research report on Tuesday, October 23rd. Finally, UBS Group set a €110.00 ($127.91) target price on shares of Bayer and gave the company a buy rating in a research report on Tuesday, January 8th. Seven equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of €88.37 ($102.76).

Shares of BAYN opened at €68.28 ($79.40) on Monday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Key terms to understand channel trading

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply